title: HIV-1 Gag C-terminal amino acid substitutions emerging under selective pressure of protease inhibitors in patient populations infected with different HIV-1 subtypes.
abstract: HIV-1 Gag amino acid substitutions associated with protease inhibitor (PI) treatment have mainly been reported in subtype B, while information on other subtypes is scarce. Using sequences from 11613 patients infected with different HIV-1 subtypes, we evaluated the prevalence of 93 Gag amino acid substitutions and their association with genotypic PI resistance. A significant association was found for 13 Gag substitutions, including A431V in both subtype B and CRF01_AE. K415R in subtype C and S451G in subtype B were newly identified. Most PI-associated Gag substitutions are located in the flexible C-terminal domain, revealing the key role this region plays in PI resistance.
authors.forename: Guangdi
authors.initials: G
authors.lastname: Li
authors.forename: Jens
authors.initials: J
authors.lastname: Verheyen
authors.forename: Kristof
authors.initials: K
authors.lastname: Theys
authors.forename: Supinya
authors.initials: S
authors.lastname: Piampongsant
authors.forename: Kristel
authors.initials: K
authors.lastname: Van Laethem
authors.forename: Anne-Mieke
authors.initials: AM
authors.lastname: Vandamme
mesh_terms: D024882:Drug Resistance, Viral; D015658:HIV Infections / Q000188:drug therapy* / Q000821:virology; D017320:HIV Protease Inhibitors / Q000627:therapeutic use*; D015497:HIV-1 / Q000145:classification*; D006801:Humans; D013329:Structure-Activity Relationship; D054301:gag Gene Products, Human Immunodeficiency Virus / Q000737:chemistry / Q000502:physiology*
chemical_list: D017320:HIV Protease Inhibitors; D054301:gag Gene Products, Human Immunodeficiency Virus